Source: Journal of Clinical Oncology. Conference titles: Gastrointestinal Cancers Symposium. Unidade: FM
Subjects: QUIMIOTERAPIA (EFEITOS ADVERSOS), NEOPLASIAS COLORRETAIS (TERAPIA), TOXICIDADE
ABNT
PROTASIO, Bruno Mendonca et al. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b. Acesso em: 04 out. 2024. , 2015APA
Protasio, B. M., Matutino, A. R. B., Lage, L. V., De Santana, I. A., Ramos, R. E. D. O., Caires-Lima, R., et al. (2015). Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49bNLM
Protasio BM, Matutino ARB, Lage LV, De Santana IA, Ramos REDO, Caires-Lima R, Caires IQDS, Riechelmann RP, Saragiotto DF, Sabbaga J, Hoff PM. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2024 out. 04 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49bVancouver
Protasio BM, Matutino ARB, Lage LV, De Santana IA, Ramos REDO, Caires-Lima R, Caires IQDS, Riechelmann RP, Saragiotto DF, Sabbaga J, Hoff PM. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2024 out. 04 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b